Interaction Checker

Interações de Macitentana

Macitentana (Opsumit) tem 117 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 77; moderadas: 0; leves: 40; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (77)

  • AmiodaronaantiarrítmicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Aprepitantoinibidor da CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Armodafinilaestimulante do SNCGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • AtazanavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Bosentanaindutor da CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Canabidiol (medicamento de prescrição)anticonvulsivanteGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • CapecitabinaantimetabólitoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • CarbamazepinaanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • CenobamatoanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Cetoconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • CiclosporinaimunossupressorGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Cimetidinabloqueador H2Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Claritromicinaantibiótico macrolídeoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • ClobazambenzodiazepínicoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • DarunavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Darunavir + cobicistateantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • DexametasonacorticosteroideGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Diltiazembloqueador dos canais de cálcioGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Dissulfiraminibidor da CYP2C9Grave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • DronedaronaantiarrítmicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • EfavirenzantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Efavirenz + lamivudina + tenofovirantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Elvitegravir + cobicistate + entricitabina + tenofovirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Eritromicinaantibiótico macrolídeoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • EslicarbazepinaanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • EtravirinaantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • EverolimoimunossupressorGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • FenitoínaanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • FenobarbitalbarbitúricoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Fentermina + topiramatoestimulante do SNCGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • FluoruracilaantimetabólitoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • FluvastatinaestatinaGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • FosamprenavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Fosaprepitantoinibidor da CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • FosfenitoínaanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • GriseofulvinaantifúngicoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Imatinibeinibidor da CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • IsoniazidaantibióticoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Ivacaftorinibidor da CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • LenacapavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Lopinavir + ritonavirantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Lorlatinibeindutor da CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • MetronidazolantibióticoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Miconazolantifúngico azólicoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Mirabegronaagonista beta-adrenérgicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Mitapivateindutor da CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Mitotanoindutor da CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Modafinilaestimulante do SNCGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Nafcilinaantibiótico da classe das penicilinasGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • NefazodonaantidepressivoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • NevirapinaantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Nirmatrelvir + ritonavirantiviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Nitisinonainibidor da CYP2C9Grave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • OxcarbazepinaanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Palbociclibeinibidor da CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • PerampanelanticonvulsivanteGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Posaconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • PrimidonaanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Ranolazinamedicamento que prolonga o intervalo QTGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • RifabutinaantibióticoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • RifampicinaantibióticoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • RifapentinaantibióticoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • RitonavirantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Subcitrato de bismuto + metronidazol + tetraciclinaantibióticoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Sulfametoxazol + trimetoprimasulfonamidaGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Suvorexantosedativo-hipnóticoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Suzetriginaindutor da CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Ticagrelorantiagregante plaquetárioGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • TopiramatoanticonvulsivanteGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • TrimetoprimaantibióticoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

  • Verapamilbloqueador dos canais de cálcioGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (bula de Macitentana, Interações medicamentosas)

  • Zafirlucasteantagonista do receptor de leucotrienosGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (bula de Macitentana, Interações medicamentosas)

Menções leves (40)

  • Acetazolamidainibidor da anidrase carbônicaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Ácido etacrínicodiurético de alçaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Amiloridadiurético poupador de potássioLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Atenolol + clortalidonabetabloqueadorLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Benazepril + hidroclorotiazidainibidor da ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Bisoprolol + hidroclorotiazidabetabloqueadorLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Bumetanidadiurético de alçaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Candesartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Clorotiazidadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Clortalidonadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Desogestrel + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Diacetato de etinodiol + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Drospirenona + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Enalapril + hidroclorotiazidainibidor da ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Eplerenonaantagonista da aldosteronaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Espironolactonaantagonista da aldosteronaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Espironolactona + hidroclorotiazidaantagonista da aldosteronaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Estradiol + dienogesteanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Fosinopril + hidroclorotiazidainibidor da ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Furosemidadiurético de alçaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Hidroclorotiazidadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Indapamidadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Irbesartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Levonorgestrel + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Lisinopril + hidroclorotiazidainibidor da ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Losartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Metolazonadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Metoprolol + hidroclorotiazidabetabloqueadorLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • NoretisteronaprogestinaLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Noretisterona + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Norgestimato + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Norgestrel + etinilestradiolanticoncepcional oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (bula de Macitentana, Advertências e precauções)

  • Olmesartana + anlodipino + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Olmesartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Quinapril + hidroclorotiazidainibidor da ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Telmisartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Torasemidadiurético de alçaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Trianterenodiurético poupador de potássioLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Triantereno + hidroclorotiazidadiurético poupador de potássioLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

  • Valsartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

Verifique Macitentana com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.